APAC Liver Cancer Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.20 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
APAC Liver Cancer Market Analysis
The Asia-Pacific liver cancer market is anticipated to register a CAGR of 5.2% over the forecast period.
The emergence of COVID-19 had a major impact on patients with diseases other than COVID-19 due to the high burden on healthcare resources, owing to the increasing infection rate of the SARS-CoV-2 virus. The liver cancer market was also impacted by the pandemic as it delayed or rescheduled diagnostics and treatment procedures. There was a decline in footfall in hospitals for treatment and diagnostics of new cancer cases as people with comorbidity were at higher risk of COVID-19. For instance, according to a research study published in NCBI in February 2021, the standard treatment of patients with liver cancer was significantly impacted by the first wave of the COVID-19 pandemic. However, with the decreasing COVID-19 cases and large-scale vaccination programs, the liver cancer market has reached its pre-pandemic level growth.
The major factors driving the market's growth include the rising burden of liver cancer, increasing R&D investments for developing novel therapies along with government initiatives to increase cancer awareness. For instance, in May 2022, a research study published by BioMed Central Ltd stated that in India more than 40% of the total cancer burden was contributed by the seven leading cancer sites including liver cancer contributing to 4.6%. Besides, around 6% of liver cancer cases resulted in a disability-adjusted life year (DALY) in males. Thus, the increasing prevalence of liver cancer is expected to create demand for advanced diagnostics and therapeutics which is expected to contribute to the market's growth over the forecast period.
Moreover, the increasing research activities and funding in the area are further expected to boost the market growth. For instance, in February 2022, Edith Cowan University of Australia received USD 2.35 million to support a new form of radiotherapy treatment for liver cancer and to conduct trials in several locations across Australia over the next five years. Hence, the huge burden of liver cancer and its risk factors, coupled with ongoing R&D activities, is expected to boost the market's growth over the forecast period.
However, factors such as side effects associated with certain medications, the high cost of cancer therapies, and stringent regulatory scenarios are expected to restrain the market growth over the forecast period.
APAC Liver Cancer Market Trends
Hepatocellular Carcinoma Segment is Expected to Witness Significant Growth over the Forecast Period
A hepatocellular carcinoma is a common form of liver cancer that occurs in people suffering from chronic liver diseases like cirrhosis. It is one of the major causes leading to cancer-related deaths. Health organizations had issued necessary guidelines and recommendations for managing hepatocellular carcinoma patients during the COVID-19 pandemic. For instance, as per the American Society of Clinical Oncology (ASCO) and the National Institute of Health and Care Excellence (NICE) proposed guidelines, the COVID-19 pandemic patients with chronic liver disease, such as hepatocellular carcinoma (HCC), and COVID-19 were recommended to admit for inpatient care. This had a positive impact on the market.
Furthermore, the prevalence rate of liver cancers is rising, which in turn, is driving the market growth. For instance, according to the NLM's data published in October 2021, liver cancer is common cancer, especially in countries such as China, Japan, South Korea, Taiwan, and Singapore. The same source also stated that one of the highest incidence rates of liver cancer was in Asia in 2021. The highest number of cases was in China due to a high incidence rate of 18.3 per 100,000 in 2021. Additionally, the same source stated that hepatocellular carcinoma (HCC), comprising 75% to 85% of primary liver cancer cases, is the fourth most common cause of cancer-related death worldwide. The source further added that Asian and African countries have higher incidence rates of hepatocellular carcinoma than the developed world due to the disparity in the major risk factors causing diseases such as hepatitis B (HBV) and hepatitis C virus (HCV) infection in these regions. Thus, increasing cases of cancer cases are driving the growth of the market.
China is Expected to Hold a Significant Share in the Market over the Forecast Period
The major factors driving the market growth in China include the rising incidence of liver cancer in the country and the presence of key market players offering novel products.
The high burden of liver cancer in the country is expected to be the primary factor for the market's growth. With the increase in liver cancer burden, the adoption and demand for treatment procedures increase in the country. This is expected to support market growth. For instance, according to the March 2022 published article in the Chinese Medical Journal, an estimated 431,383 people in 2022 were diagnosed with liver cancer in China. Thus, the high burden of liver cancer is fuelling the market's growth. Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver cancer and develops predominantly in those people with cirrhosis, or scarring, due to chronic hepatitis B or C. This is expected to have a positive impact on the liver cancer therapeutics market. Thus, the high burden of liver cancer is fueling the market's growth.
Furthermore, in China, approvals of novel therapeutics for liver cancer are also expected to drive market growth. For instance, in October 2022, China's National Medical Products Administration (NMPA) approved the expanded use of Eli Lilly and Innovent Biologics' Cyramza to treat certain patients with a type of liver cancer. Thus, such approvals are expected to increase market growth in the country over the forecast period.
Therefore, the increased incidence of liver cancer in China with the availability of liver cancer treatment is expected to drive the market over the forecast period.
APAC Liver Cancer Industry Overview
The Asia-Pacific liver cancer market is highly competitive due to the presence of a large number of companies. The competitive landscape includes an analysis of a few international and local companies that hold significant market shares. Some of the players operating in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co. Inc., Sanofi SA, Novartis AG, Epigenomics AG, Pfizer Inc. among others.
APAC Liver Cancer Market Leaders
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Boston Scientific Corporation
Bayer AG
Siemens Healthineers GmbH
*Disclaimer: Major Players sorted in no particular order
APAC Liver Cancer Market News
- In January 2022, Merck received conditional liver cancer treatment approval for its drug Keytruda based on its second confirmatory study.
- In January 2022, the LAUNCH trial conducted in China supported a potential new first-line treatment option for selected patients with advanced hepatocellular carcinoma (HCC).
APAC Liver Cancer Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Liver Cancer
4.2.2 Increasing R&D Investments for the Development of Novel Therapies
4.2.3 Government Initiatives to Increase Cancer Awareness
4.3 Market Restraints
4.3.1 Side Effects Associated with Certain Medications Coupled with High Cost of Cancer Therapies
4.3.2 Stringent Regulatory Scenario
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Cancer Type
5.1.1 Primary Cancer
5.1.1.1 Hepatocellular Carcinoma
5.1.1.2 Hepatoblastoma
5.1.1.3 Other Primary Cancer
5.1.2 Secondary Cancer
5.1.2.1 Hemangioma
5.1.2.2 Hepatic adenoma
5.1.2.3 Other Secondary Liver Cancer
5.2 By Type
5.2.1 Diagnostic
5.2.1.1 Ultrasound Scans
5.2.1.2 Confirmatory Needle Biopsy
5.2.1.3 Endoscopic Ultrasound
5.2.1.4 CT Scan
5.2.1.5 PET Scan
5.2.1.6 Other Diagnostic Types
5.2.2 Therapeutics
5.2.2.1 Targeted Therapy
5.2.2.2 Radiation Therapy
5.2.2.3 Immunotherapy
5.2.2.4 Chemotherapy
5.3 By End User
5.3.1 Hospitals
5.3.2 Other End Users
5.4 Geography
5.4.1 China
5.4.2 Japan
5.4.3 India
5.4.4 Australia
5.4.5 South Korea
5.4.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 Boston Scientific Corporation
6.1.4 Siemens Healthcare GmbH
6.1.5 Bayer AG
6.1.6 Merck & Co. Inc.
6.1.7 Sanofi SA
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Eli Lilly and Company
6.1.11 Bristol-Myers Squibb Company
6.1.12 Exelixis Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
APAC Liver Cancer Industry Segmentation
As per the scope of the report, liver cancer is a chronic, life-threatening, and progressive disorder that begins in the cells of the liver. Liver cancer can be of different types, such as cancer that begins in hepatocyte cells, known as primary hepatic cancer, and cancer that spreads to the liver from other parts of the body, known as metastatic cancer. The Asia-Pacific Liver Cancer Market is Segmented by Cancer Type (Primary Liver Cancer (Hepatocellular Carcinoma (HCC), Hepatoblastoma, Other Primary Liver Cancer), Secondary Liver Cancer (Hemangioma, Hepatic adenoma, Other Secondary Liver Cancer), Type (Diagnostic (Ultrasound Scans, Confirmatory Needle Biopsy, Endoscopic Ultrasound, CT Scan, PET Scan, and Other Diagnostic), and Therapeutics (Targeted Therapy, Radiation Therapy, Chemotherapy, and Other Therapeutics), End User (Hospitals and Other End Users), and Geography (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific). The report offers the value (USD million) for the above segments. The report offers the value (USD million) for the above segments.
| By Cancer Type | |||||
| |||||
|
| By Type | ||||||||
| ||||||||
|
| By End User | |
| Hospitals | |
| Other End Users |
| Geography | |
| China | |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific |
APAC Liver Cancer Market Research FAQs
What is the current Asia Pacific Liver Cancer Market size?
The Asia Pacific Liver Cancer Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Asia Pacific Liver Cancer Market?
Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Bayer AG and Siemens Healthineers GmbH are the major companies operating in the Asia Pacific Liver Cancer Market.
What years does this Asia Pacific Liver Cancer Market cover?
The report covers the Asia Pacific Liver Cancer Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia Pacific Liver Cancer Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Asia Pacific Liver Cancer Industry Report
Statistics for the 2024 Asia Pacific Liver Cancer market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Asia Pacific Liver Cancer analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
